Eisai Clinical Trials
Study Overview
BB-1701
N/A
NCT06188559, 2023-506866-30
Apr 2024 -
Breast Cancer
1. Part 1, Dose Optimization: Number of Participants With Adverse Events (AEs) [Time Frame: Baseline up to 35 months]
2. Part 1, Dose Optimization: Number of Participants With Clinically Significant Laboratory Values [Time Frame: Baseline up to 35 months]
3. Part 1, Dose Optimization: Number of Participants With Clinically Significant Vital Sign Values [Time Frame: Baseline up to 35 months]
4. Part 1, Dose Optimization: Number of Participants With Clinically Significant 12-lead ECGs Values [Time Frame: Baseline up to 35 months]
2. Part 1, Dose Optimization: Number of Participants With Clinically Significant Laboratory Values [Time Frame: Baseline up to 35 months]
3. Part 1, Dose Optimization: Number of Participants With Clinically Significant Vital Sign Values [Time Frame: Baseline up to 35 months]
4. Part 1, Dose Optimization: Number of Participants With Clinically Significant 12-lead ECGs Values [Time Frame: Baseline up to 35 months]
-
Males and females 18 Years and older (Adult, Older Adult)
-
Active, not recruiting -
Phase 2
France, Germany, Japan, Spain, United States See moreData Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
CSDR Sharing is not available for this study.
CSDR Availability Clinical Trial Data Redacted documents may be available upon request for this study.
Document type Availability Protocol SAP Sample CRF Full CSR